Clinical management of osteoporosis in women with a history of breast carcinoma (Q36169511)

12 August 2017

1 reference

title

Clinical management of osteoporosis in women with a history of breast carcinoma (English)

1 reference

12 August 2017

0 references

Catherine Van Poznak

1

1 reference

12 August 2017

Nicholas P Sauter

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

104

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

443-456

1 reference

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

Body mass index and post-menopausal breast cancer: an age-specific analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The osteoblast: a sophisticated fibroblast under central surveillance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Pathogenesis of bone fragility in women and men.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Epidemiology and outcomes of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Osteoporosis due to cancer treatment: pathogenesis and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Is there a reduced risk of breast cancer among women with hip fractures?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The epidemiology of serum sex hormones in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Stage of breast cancer in relation to body mass index and bra cup size

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Bone mass and breast cancer risk in older women: differences by stage at diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Osteopenia and osteoporosis in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Risk of menopause during the first year after breast cancer diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Shock wave application enhances pertussis toxin protein-sensitive bone formation of segmental femoral defect in rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Chemical and morphologic alterations of rabbit bone induced by adriamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The short- and long-term effects of methotrexate on the rat skeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Fracture risk after bilateral oophorectomy in elderly women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The prevention and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Prevention of hip fracture in elderly people with use of a hip protector

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21201

7 January 2021

Identifiers

DOI

10.1002/CNCR.21201

1 reference

12 August 2017

1 reference